Cannabis Law and Access in Colombia

Cannabis law in Colombia, explained from the outside

Forty-three countries now have some form of regulated cannabis access. Australian patients and researchers ask about international comparators constantly, and comparing regulatory architectures is, honestly, one of the more interesting puzzles in drug policy. Colombia sits near the top of that list for sheer ambition. Its cannabis law is detailed, export-oriented, and considerably older than most people realise.

A note before anything else: this article describes Colombian law as it stands. It is not Australian law. Australian access to medicinal cannabis operates under a separate federal framework: the Therapeutic Goods Administration (TGA), the Poisons Standard, and pathways including the Special Access Scheme and the Authorised Prescriber programme. Those are the frameworks that apply to you if you're in Australia. What follows is a factual account of what Colombia has built, written for education rather than as guidance on what anyone should do.

If you want the Australian side first, our explainer on the Therapeutic Goods Administration is the best starting point. It makes the Colombian comparison easier to follow, because the two systems are built on quite different assumptions.

Law 1787, Decree 613 and the licence categories

The historical foundation

Colombia legalised the cultivation, production, and export of cannabis for medicinal and scientific purposes in 2016 under Law 1787. That law amended earlier provisions of Law 30 (1986), which had governed narcotics in Colombia for decades. The implementing regulation, Decree 613 of 2017, established the licence categories, the oversight bodies, and the technical standards that govern the industry.

The distinction between a statute and its implementing decree is worth understanding. A law sets the principle; a decree supplies the operational detail, such as who may apply, what must be reported and which inspections apply. Readers who only see the headline year often miss that a legal change and a working licensing system are two separate milestones.

2016 is not recent. By the time Australia's own TGA rescheduled medicinal cannabis products under the Poisons Standard in February 2017, Colombia already had a signed law and a working regulatory structure in development. For the Australian timeline, see our piece on Australia's 2016 medicinal cannabis legalisation. The Colombians were early movers, and the framework reflects that. It has been amended and refined repeatedly since, which is usually a sign of a framework that's actually being used.

The Ministry of Justice and Law and the Ministry of Health jointly administer the licensing regime. The Colombian Agricultural Institute (ICA) handles cultivation licences. This split-agency model is notable; it reflects the fact that cannabis regulation in Colombia straddles agriculture, public health, and criminal law simultaneously. Australia splits responsibility too, between federal and state bodies, as our overview of state versus federal drug regulation explains.

What the licences cover

Under the Colombian framework, there are four main licence categories:

• Cultivation of psychoactive cannabis seed, for plants with THC above 1%
• Cultivation of non-psychoactive cannabis seed, for plants at or below 1% THC, often cultivated for cannabidiol (CBD) and other non-intoxicating cannabinoids
• Manufacture of cannabis derivatives, covering extraction and transformation into finished or semi-finished products
• Use of cannabis seeds for planting purposes, a narrower licence for seed management and propagation

Each licence category carries its own technical, security, and reporting requirements. That layering is typical of any system that licenses a controlled substance: the further along the chain from seed to finished product, the more oversight tends to apply, because each step creates a different diversion risk.

Manufacturers working with psychoactive material operate under quota systems aligned with Colombia's international obligations under the 1961 UN Single Convention on Narcotic Drugs, the same treaty architecture that shapes scheduling decisions in Australia and most other signatory nations. The Single Convention on Narcotic Drugs is the place to start if you want to see why national systems for controlled substances look so structurally similar.

Personal use and decriminalisation

This is the part that tends to generate confusion in online discussions, so I'll be deliberate here.

Colombia's Constitutional Court ruled in 1994 (Sentence C-221) that personal possession of cannabis in small quantities for personal use could not be criminalised under the right to free personal development enshrined in the 1991 Constitution. A subsequent legal dose, commonly cited as up to 20 grams, has been treated as a "personal dose" threshold, though the legal interpretation has shifted over the years depending on government and enforcement priorities.

This is decriminalisation, not legalisation of recreational use. Sale, trafficking, and supply outside the licensed medicinal/scientific framework remain criminal offences under Colombian law. The distinction matters enormously. A decriminalised possession threshold does not constitute a legal retail market.

The common mistake is to treat the two ideas as interchangeable. Decriminalisation removes or reduces criminal penalties for a defined behaviour; legalisation creates a lawful, regulated way to supply and sell. A country can have the first without the second, and Colombia is a clear example. When an overseas headline says cannabis is "legal" somewhere, the useful questions are: legal for whom, in what quantity, and through which licensed channel?

Various attempts to pass recreational legalisation legislation have been made in the Colombian Congress since the mid-2010s, but as of the time of writing, no comprehensive adult-use retail framework has passed into law. The situation is politically fluid.

Export: where Colombia's framework became globally significant

Law 2204 of 2022 authorised the export of dried cannabis flower for the first time, a significant expansion. Prior to this, Colombian exports were limited to extracts, oils, and processed derivatives. The 2022 law opened the door to whole-flower exports, which carry different regulatory complexity, particularly around Good Manufacturing Practice standards, which you can read about in our GMP glossary entry.

Why would flower be harder than an oil? A processed extract can be tested and standardised batch by batch. Dried flower is a botanical material, so consistency, contamination controls, handling and traceability all become harder to demonstrate. Importing countries generally want evidence that a product was made to a recognised quality standard, whatever form it takes.

Colombia's geographic position and growing conditions mean that outdoor cultivation costs are substantially lower than in most European or North American regulated markets. The country had, by some estimates, the largest licensed cannabis cultivation area of any nation by 2021. Whether that translates into long-term export dominance will depend on whether destination-market regulatory frameworks, including the EU's evolving medicinal cannabis standards, align with Colombian production standards. That's not guaranteed.

I'll admit this is the part of the Colombian story I find genuinely fascinating from a regulatory architecture standpoint. Building an export-facing framework while simultaneously managing international treaty obligations and domestic decriminalisation is not a simple task. The Colombian regulators have had to write rules for a situation most treaty drafters in the 1960s never anticipated.

CBD and the non-psychoactive track

Non-psychoactive cannabis, meaning plants at or below the 1% THC threshold, sits in a somewhat more straightforward regulatory lane. Cultivation licences for non-psychoactive material are less restrictive, and the resulting extracts, including CBD-dominant preparations, have fed a domestic market for phytomedicine products and an export market for ingredients.

The chemistry of what's in those products is worth understanding. CBD is only one of dozens of cannabinoids present in cannabis extracts. Depending on whether a product is full-spectrum, broad-spectrum, or an isolate, the cannabinoid and terpene profile varies substantially. A full-spectrum extract retains a wider range of plant compounds, a broad-spectrum extract retains many but is processed to remove certain ones, and an isolate is a single purified compound. Those labels describe composition, not quality or effect.

Colombian manufacturers producing for export have had to grapple with destination-market definitions. What counts as "CBD extract" in Germany, Canada, or Australia is not always the same thing. A product described one way on a certificate of analysis may be classified differently once it crosses a border, which is why reading the legal definition in the importing jurisdiction matters more than reading the marketing language on the label.

What this means for Australian readers

Practically nothing, in terms of what you can do or access in Australia. I say that plainly because overseas frameworks are easy to misread, and it is common for people to draw incorrect conclusions about their own options from them.

In Australia, cannabis-derived medicines are either listed on the Australian Register of Therapeutic Goods (ARTG) or accessed via unapproved pathways, a topic covered in our explainer on the legal basis for unapproved therapeutic goods. Medicinal cannabis products containing THC are regulated as Schedule 8 controlled drugs under the Poisons Standard. CBD products above certain concentrations are Schedule 4 prescription-only medicines. None of that changes because Colombia has a different framework. If the scheduling terminology is unfamiliar, the Poisons Standard (SUSMP) explained covers how it works, and the medicinal cannabis access FAQ answers the questions readers raise most often.

What the Colombian framework does offer is a useful comparative reference. It demonstrates one approach to managing the tension between international treaty obligations, domestic public health priorities, and economic opportunity in the cannabis sector. Australian policymakers and researchers cite international comparators regularly, Colombia, Canada, the Netherlands, when evaluating whether existing Australian access pathways are calibrated correctly.

In my view, the more interesting comparative question isn't "how liberal is Colombia" but rather "how does a middle-income country with significant agricultural capacity build GMP-compliant export infrastructure from scratch." That's a harder problem than it looks, and the Colombian experience from 2017 onwards has been instructive precisely because it hasn't been smooth. Frameworks that get amended repeatedly are showing their working in public, and I'd argue that's more reassuring than a rulebook that claims to have got everything right first time.

One last practical point on method. When you read about any foreign cannabis regime, check the date of the source, check whether it describes a law, a decree or a court ruling, and check whether it is talking about medicinal, scientific or personal use. Those three checks prevent most of the misunderstandings that circulate online.

Sources

• Cannabis; Drug Trafficking, UNODC
• Medicinal Cannabis Regulation in Latin America: A Comparative Analysis, NCBI/PMC
• Cannabis; WHO
• Medicinal cannabis: information for patients and caregivers, TGA

Marcus Hale, Regulatory researcher, TGA & access law